• Citer

Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.

par Mano, Max S.;Awada, Ahmad ;Minisini, A;Durbecq, Virginie ;Di Leo, Angelo ;Piccart-Gebhart, Martine
Référence Breast, 13, 4, page (347-349)
Publication Publié, 2004-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.
Auteur:	Mano, Max S.; Awada, Ahmad; Minisini, A; Durbecq, Virginie; Di Leo, Angelo; Piccart-Gebhart, Martine
Informations sur la publication:	Breast, 13, 4, page (347-349)
Statut de publication:	Publié, 2004-08
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	Breast cancer
	Epithelial growth factor
	Raf kinase inhibitors
	Survival pathways
	Trastuzumab
MeSH keywords:	1-Phosphatidylinositol 3-Kinase
	Antibodies, Monoclonal -- therapeutic use
	Antineoplastic Agents -- therapeutic use
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- genetics
	Breast Neoplasms -- immunology
	Drug Resistance, Neoplasm
	Female
	Genes, ras
	Humans
	Middle Aged
	Mitogen-Activated Protein Kinase Kinases
	Receptor, erbB-2 -- genetics
	Treatment Outcome
	raf Kinases
Note générale:	Case Reports
	Journal Article
Langue:	Anglais
Identificateurs:	urn:issn:0960-9776
	info:doi/10.1016/j.breast.2003.11.009
	info:pii/S0960977604000153
	info:scp/4444248291
	info:pmid/15325672